About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Managing R/R-transformed DLBCL remains a challenge, as affected patients have an approximate 27% chance of 4-year event-free survival and a 39% chance of overall survival. 2 Atezolizumab is a ...

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

In part 2 of this interview with Frederick L. Locke, MD, lead investigator on the phase 1 ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials of allogeneic chimeric antigen receptor T-cell therapy ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into ...

Up to one-third of all people with non-Hodgkin's lymphoma have diffuse large B-cell lymphoma (DLBCL). DLBCL grows quickly, but it's possible to cure it. Most people learn they have this type after ...

Decision-making to treat in the frontline is based on histology, disease burden and patient symptoms. The general approach should be a combination of rituximab and chemotherapy, traditionally ...

June 20, 2024 — Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to ...

Now in its sixth year, OncomineWorld meetings have united thousands of scientists and professionals from around the globe to advance genomic profiling in clinical oncology research. The agenda will ...